RxDoctor Payments Data

Michelle Ortega

Nurse Practitioner · Gurnee, ILNPI 1073531547

Payments from drug & device makers

$1,770in general payments, 2019–2025

Across 56 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$430
  • Boehringer Ingelheim$206
  • AstraZeneca$180
  • Actelion Pharmaceuticals US, Inc.$149
  • Johnson & Johnson$146
  • Regeneron Healthcare Solutions, Inc.$124
  • plus $536 from 11 others

What the payments were for

  • Food & beverage$1,68095%
  • Education$905%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,770 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$71,405
Medicare patients
440
Services billed
1,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter237$231,151
Breztri AerosphereBudesonide/Glycopyr/Formoterol68$49,010
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$42,231
Spiriva RespimatTiotropium Bromide53$33,957
Breo ElliptaFluticasone/Vilanterol48$31,696
Advair HfaFluticasone Propion/Salmeterol48$27,479
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$25,471
DuleraMometasone/Formoterol40$21,220
SymbicortBudesonide/Formoterol Fumarate47$21,176
Wixela InhubFluticasone Propion/Salmeterol67$14,844
Incruse ElliptaUmeclidinium Bromide26$13,616
Advair DiskusFluticasone Propion/Salmeterol38$9,382
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$9,201
Pirfenidone14$9,049
Albuterol Sulfate HfaAlbuterol Sulfate281$8,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort$180$70,186115 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$206$59,42885 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Gurnee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →